Neuphoria Therapeutics Inc. (NEUP) bonds

NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026Score 5/30

$2.58−0.13 (-4.80%)

Close on Nov 12, 2026Market cap $77.56KP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Individual notes, bonds and loans

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

Parsed from the XBRL in Neuphoria Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2160 reverse split on Feb 14, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NEUP.

Revenue growth-92.5% · median -46.7%

Operating margin-1401.1% · median -2843.5%

Net margin-1145.7% · median -1836.7%

Advertisement
300 × 250

See a number that looks wrong?